›2.↳ 1A compound according to claim 1 wherein the compound is selected from the group consisting of a compound of formula (Io):d2
A compound according to claim 1 wherein the compound is selected from the group consisting of a compound of formula (Io):
›3.↳ 1A compound according to claim 1 wherein n represents 0, 1 or 2;nor an N-oxide thereof or a pharmaceutically acceptable salt thereof.d2
A compound according to claim 1 wherein n represents 0, 1 or 2;nor an N-oxide thereof or a pharmaceutically acceptable salt thereof.
›4.↳ 1A compound according to claim 1 wherein R1 is C1-6alkyl;nor an N-oxide thereof or a pharmaceutically acceptable salt thereof.d2
A compound according to claim 1 wherein R1 is C1-6alkyl;nor an N-oxide thereof or a pharmaceutically acceptable salt thereof.
›5.↳ 1A compound according to claim 1 wherein R2 is C1-4alkoxy;nor an N-oxide thereof or a pharmaceutically acceptable salt thereof.d2
A compound according to claim 1 wherein R2 is C1-4alkoxy;nor an N-oxide thereof or a pharmaceutically acceptable salt thereof.
›6.↳ 1A compound according to claim 1 wherein R3a is —NR10R11, hydroxyl, hydroxyC1-6alkyl, cyanoC1-6alkyl, C1-6alkyl substituted with —C(â• O)—C1-6alk…d2
A compound according to claim 1 wherein R3a is —NR10R11, hydroxyl, hydroxyC1-6alkyl, cyanoC1-6alkyl, C1-6alkyl substituted with —C(╠O)—C1-6alkyl, C1-6alkyl substituted with —C(╠O)—O—C1-6alkyl, C1-6alkyl substituted with R9, C1-6alkyl substituted with —NR10R11, C1-6alkyl substituted with hydroxyl and —NR10R11, C1-6alkyl substituted with —C(╠O)—NR10R11;nor an N-oxide thereof or a pharmaceutically acceptable salt thereof.
›7.↳ 1A compound according to claim 1 wherein R3a and R3b are taken together to form â• O, to form cyclopropyl together with the carbon atom to which they a…d2
A compound according to claim 1 wherein R3a and R3b are taken together to form ╠O, to form cyclopropyl together with the carbon atom to which they are attached, to form ╠CH—C0-4alkyl substituted with R3c, or to form
›8.↳ 1A compound according to claim 1 wherein R3c represents hydroxyl, —NR10R11, cyano, or —C(â• O)—C1-6alkyl;nor an N-oxide thereof or a pharmaceutic…d2
A compound according to claim 1 wherein R3c represents hydroxyl, —NR10R11, cyano, or —C(╠O)—C1-6alkyl;nor an N-oxide thereof or a pharmaceutically acceptable salt thereof.
›9.↳ 1A compound according to claim 1 wherein R9 is a monocyclic heterocyclyl containing at least one heteroatom selected from N, O and S, said monocyclic h…d2
A compound according to claim 1 wherein R9 is a monocyclic heterocyclyl containing at least one heteroatom selected from N, O and S, said monocyclic heterocyclyl optionally being substituted with 1 substituent selected from â• O and C1-4alkyl;nor an N-oxide thereof or a pharmaceutically acceptable salt thereof.
›10.↳ 1A compound according to claim 1 wherein R10 and R11 each independently represent hydrogen, C1-6alkyl, C1-6alkyl substituted with —NR14R15 or haloC1-…d2
A compound according to claim 1 wherein R10 and R11 each independently represent hydrogen, C1-6alkyl, C1-6alkyl substituted with —NR14R15 or haloC1-6alkyl;nor an N-oxide thereof or a pharmaceutically acceptable salt thereof.
›11.↳ 1A compound according to claim 1 wherein R14 and R15 each independently represent hydrogen or C1-4alkyl;nor an N-oxide thereof or a pharmaceutically ac…d2
A compound according to claim 1 wherein R14 and R15 each independently represent hydrogen or C1-4alkyl;nor an N-oxide thereof or a pharmaceutically acceptable salt thereof.
›12.↳ 1A compound as defined in claim 1 or a pharmaceutically acceptable salt thereof.d2
A compound as defined in claim 1 or a pharmaceutically acceptable salt thereof.
›13.↳ 1A compound according to claim 1 wherein the compound is selected fromn{(Z)-3-(3,5-Dimethoxy-phenyl)-3-[3-(1-methyl-1H-pyrazol-4-yl)-quinoxalin-6-yl]-a…d2+4
A compound according to claim 1 wherein the compound is selected fromn{(Z)-3-(3,5-Dimethoxy-phenyl)-3-[3-(1-methyl-1H-pyrazol-4-yl)-quinoxalin-6-yl]-allyl}-dimethyl-amine;{(Z)-3-(3,5-Dimethoxy-phenyl)-3-[3-(1-methyl-1H-pyrazol-4-yl)-quinoxalin-6-yl]-allyl}-isopropyl-amine;{(Z)-3-(3,5-Dimethoxy-phenyl)-3-[3-(1-methyl-1H-pyrazol4-yl)-quinoxalin-6-yl]-allyl}-(2,2,2-trifluoro-ethyl)-amine;{(S)-3-(3,5-Dimethoxy-phenyl)-3-[3-(1-methyl-1H-pyrazol-4-yl)-quinoxalin-6-yl]-propyl}-isopropyl-amine; and{3-(3,5-Dimethoxy-phenyl)-3-[3-(1-methyl-1H-pyrazol-4-yl)-quinoxalin-6-yl]-propyl}-isopropyl-amine;or an N-oxide thereof or a pharmaceutically acceptable salt thereof.
›14.↳ 13A compound according to claim 13 or a pharmaceutically acceptable salt thereof.d3
A compound according to claim 13 or a pharmaceutically acceptable salt thereof.
›16.↳ 13A pharmaceutical composition comprising a pharmaceutically acceptable carrier and/or excipient, and a compound as defined in claim 13; or an N-oxide t…d3
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and/or excipient, and a compound as defined in claim 13; or an N-oxide thereof or a pharmaceutically acceptable salt thereof.
›19.↳ 13A method for inhibiting a fibroblast growth factor receptor (FGFR) kinase, which method comprises contacting the kinase with a compound as defined in …d3
A method for inhibiting a fibroblast growth factor receptor (FGFR) kinase, which method comprises contacting the kinase with a compound as defined in claim 13,nor an N-oxide thereof or a pharmaceutically acceptable salt thereof.
›20.↳ 13multiple · 13, 19A method according to claim 19, comprising contacting the kinase with a compound as defined in claim 13 or a pharmaceutically acceptable salt thereof.d3
Multiple dependency — claims 13, 19. Shown here under 13; it stands on every one of them.
A method according to claim 19, comprising contacting the kinase with a compound as defined in claim 13 or a pharmaceutically acceptable salt thereof.
›15.↳ 1A pharmaceutical composition comprising a pharmaceutically acceptable carrier and/or excipient, and a compound as defined in claim 1; or an N-oxide th…d2
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and/or excipient, and a compound as defined in claim 1; or an N-oxide thereof or a pharmaceutically acceptable salt thereof.
›17.↳ 1A method for inhibiting a fibroblast growth factor receptor kinase, which method comprises contacting the kinase with a compound as defined in claim 1…d2
A method for inhibiting a fibroblast growth factor receptor kinase, which method comprises contacting the kinase with a compound as defined in claim 1,nor an N-oxide thereof or a pharmaceutically acceptable salt thereof.
›18.↳ 1multiple · 1, 17A method according to claim 17, comprising contacting the kinase with a compound as defined in claim 1 or a pharmaceutically acceptable salt thereof.d2
Multiple dependency — claims 1, 17. Shown here under 1; it stands on every one of them.
A method according to claim 17, comprising contacting the kinase with a compound as defined in claim 1 or a pharmaceutically acceptable salt thereof.
